Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2025-12-30 @ 7:05 PM
Study NCT ID:
NCT02257567
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2014-10-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Organization:
Study Modules
Identification Module
Status Module
Sponsor Collaborators Module
Oversight Module
Description Module
Conditions Module
Design Module
Arms Interventions Module
Outcomes Module
Eligibility Module
Contacts Locations Module
References Module
Adverse Events Module
Baseline Characteristics Module
Participant Flow Module